Development of asthma therapy with rAAV-mediated AMCase shRNA

Details Development of asthma therapy with rAAV-mediated AMCase shRNA Development of asthma therapy with rAAV-mediated AMCase shRNA

2008-12-04

2010-12-14

McGarry, Sean (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C536S024300, C536S024330

Reexamination Certificate

active

07851616

ABSTRACT:
The invention provides small interfering RNA (siRNA) and their carriers that could treat asthma in mammalian through inhibiting acidic mammalian chitinase (AMCase) gene expression. The invention further provides a composition comprising siRNA of the present invention and a carrier. The invention also provides a method for treating asthma of a subject.

REFERENCES:
patent: 7214373 (2007-05-01), Elias et al.
patent: 2005/0214297 (2005-09-01), Mao et al.
Scanlon, KJ (Current Pharmaceutical Biotechnology, 2004 vol. 5:415-420).

Affiliated with

Also associated with

Rating

Development of asthma therapy with rAAV-mediated AMCase shRNA does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Development of asthma therapy with rAAV-mediated AMCase shRNA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Development of asthma therapy with rAAV-mediated AMCase shRNA will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4195647